IDH突变型2/3级胶质瘤首次进展后替莫唑胺再挑战的疗效
本研究回顾性分析了15例WHO 2016分级II/III级IDH突变型胶质瘤患者在首次进展后再次接受替莫唑胺(TMZ)治疗的影像学结局。结果显示,再治疗期间肿瘤生长速率较进展前一年加快,RANO标准下无影像学缓解,提示此类肿瘤对TMZ再挑战普遍耐药,需探索替代方案。
要点
- 首次TMZ疗程结束至再治疗的中位时间为47个月。
- 再治疗中位无进展生存期27.4个月,中位总生存期47.8个月。
- RANO标准下无影像学缓解,多数肿瘤生长速率加快。
核心结论
- 既往治疗过的进展性IDH突变型胶质瘤通常对TMZ再挑战耐药,需替代方法。
研究设计与样本
- 回顾性综述2007至2019年15例WHO 2016分级II/III级IDH突变型胶质瘤首次进展后接受TMZ再治疗的患者。
- 再治疗期间为3至41个月,采用RANO标准评估缓解率。
主要发现
- 再治疗中位无进展生存期27.4个月,中位总生存期47.8个月。
- 双维乘积平均肿瘤生长速率从进展前一年的0.29 cm2/月增至再治疗期间的0.47 cm2/月。
- 体积平均肿瘤生长速率从进展前一年的1.12 cc/月增至再治疗期间的1.29 cc/月。
- 5例患者肿瘤生长速率下降,其中3例二维测量肿瘤缩小,这3例中2例三维测量也缩小。
- RANO标准下无影像学缓解。
关键数值与推荐
- RANO标准评估无影像学缓解。
- 双维乘积生长速率再治疗期间0.47 cm2/月,进展前一年0.29 cm2/月。
- 体积生长速率再治疗期间1.29 cc/月,进展前一年1.12 cc/月。
临床怎么用
- IDH突变型2/3级胶质瘤首次进展后,TMZ再挑战的影像学缓解率低,不应常规期望显著获益。
- 再治疗前肿瘤生长速率可作为参考,但需注意个体差异,部分患者仍可能生长减慢或缩小。
局限性
- 样本量小(15例),为回顾性研究。
- 再治疗期间范围宽(3至41个月),异质性较大。
- 缺乏对照组,无法直接比较再治疗与未治疗或其他方案的疗效。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with WHO grade 2 and 3 isocitrate dehydrogenase mutation (IDHmt) gliomas commonly receive temozolomide (TMZ), with or without radiation therapy, as initial therapy. At progression, TMZ is sometimes reinstated despite a paucity of data on effectiveness. METHODS: We reviewed imaging outcomes of patients with WHO 2016 grade II/III IDHmt gliomas re-treated with TMZ at first progression between 2007 and 2019. Tumor growth rates were calculated over the year preceding re-treatment and throughout the re-treatment period, ranging from 3 to 41 months. RANO criteria were utilized to assess TMZ response rate. RESULTS: 15 subjects included six grade II, five grade III oligodendrogliomas, one grade II and three grade III astrocytomas. Median time between completion of the first TMZ course and initiation of re-treatment was 47 months. Median progression-free survival with TMZ re-treatment was 27.4 months and median overall survival was 47.8 months. Mean rate of tumor growth by bidimensional product increased from 0.29 cm2 /month, in the year prior to first tumor progression, to 0.47 cm2/month during re-treatment, ranging from 3 to 41 months, with monotherapy TMZ. Volumetric mean rate of tumor growth was 1.12 cc/month in the year prior to first tumor progression versus 1.29 cc/month during TMZ re-treatment. Five patients experienced tumor growth rate reduction, of whom 3 patients experienced tumor shrinkage as measured by 2D; 2 of these 3 patients also experienced tumor shrinkage as measured by 3D. There was no radiographic response by RANO criteria. CONCLUSION: These findings suggest previously treated, progressive IDHmt gliomas are generally resistant to TMZ, underscoring the need for alternative approaches.
引用
- Yogendran LV, Kareddy A, Abbas SO, et al. Effects of re-challenge with temozolomide in grade 2/3 IDH mutant gliomas at first progression. J Neurooncol. 2025. PMID: 40836201. doi:10.1007/s11060-025-05087-w
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。